Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease

Kidney International

Volumn 84, Issue 2, 2013, Pages 381-389

  Mallamaci, Francesca ^a   Minutolo, Roberto ^b   Leonardis, Daniela ^a   D'Arrigo, Graziella ^a   Tripepi, Giovanni ^a   Rapisarda, Francesco ^c   Cicchetti, Teresa ^d   Maimone, Igina ^d   Enia, Giuseppe ^a   Postorino, Maurizio ^a   Santoro, Domenico ^e   Fuiano, Giorgio ^f   De Nicola, Luca ^b   Conte, Giuseppe ^b   Zoccali, Carmine ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Nephrology and Dialysis Unit   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

BP variability; Cardiovascular risk; Chronic kidney disease

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INCIDENCE; ITALY; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFFICE VISITS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS;

EID: 84881173852     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.132     Document Type: Article

References (57)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-180.
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169. (Pubitemid 37337595)
3. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13(Suppl 1): S37-S40. (Pubitemid 34008176)
4. Dirks JH, de Zeeuw D, Agarwal SK et al. Prevention of chronic kidney and vascular disease: toward global health equity-the Bellagio 2004 Declaration. Kidney Int Suppl 2005; 98: S1-S6.
5. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J 2011; 32: 1599-1604.
6. Bakris G, Vassalotti J, Ritz E et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 2010; 78: 726-736.
7. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774. (Pubitemid 20106689)
8. Kikuya M, Hansen TW, Thijs L et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007; 115: 2145-2152. (Pubitemid 46659066)
9. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-290.
10. http://www.kdigo.org/nephrology-guideline-database/guideline-overviews. php 2012.
11. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716. (Pubitemid 40216499)
12. Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 507-512.
13. Minutolo R, Agarwal R, Borrelli S et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011; 171: 1090-1098.
14. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375: 938-948.
15. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
16. Rothwell PM, Howard SC, Dolan E et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-480.
17. Webb AJ, Fischer U, Mehta Z et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915.
18. Howard SC, Rothwell PM. Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. Cerebrovasc Dis 2009; 28: 331-340.
19. Kotsis V, Stabouli S, Karafillis I et al. Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). Atherosclerosis 2011; 219: 194-199.
20. Tatasciore A, Zimarino M, Renda G et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2008; 31: 2137-2146.
21. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension 2012; 59: 755-762.
22. Narkiewicz K, Winnicki M, Schroeder K et al. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension 2002; 39: 168-172. (Pubitemid 34098106)
23. Ganta CK, Lu N, Helwig BG et al. Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system. Am J Physiol Heart Circ Physiol 2005; 289: H1683-H1691. (Pubitemid 41369013)
24. Webb AJ, Fischer U, Rothwell PM. Effects of beta-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011; 77: 731-737.
25. Frattola A, Parati G, Cuspidi C et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133-1137. (Pubitemid 23307888)
26. Kario K, Matsuo T, Kobayashi H et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135. (Pubitemid 26017692)
27. Hata Y, Kimura Y, Muratani H et al. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res 2000; 23: 553-560. (Pubitemid 32040795)
28. Hata Y, Muratani H, Kimura Y et al. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens 2002; 16: 141-146. (Pubitemid 34182924)
29. Grove JS, Reed DM, Yano K et al. Variability in systolic blood pressure-a risk factor for coronary heart disease? Am J Epidemiol 1997; 145: 771-776. (Pubitemid 27188513)
30. Muntner P, Shimbo D, Tonelli M et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57: 160-166.
31. Tozawa M, Iseki K, Yoshi S et al. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 1976-1981. (Pubitemid 29358897)
32. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70: 26-33. (Pubitemid 44000117)
33. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576. (Pubitemid 38591003)
34. Neumann J, Ligtenberg G, Klein IH et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-510.
35. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92: 3206-3211.
36. Converse RL Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918. (Pubitemid 23006966)
37. Siddiqi L, Prakken NH, Velthuis BK et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010; 25: 3272-3277.
38. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-46. (Pubitemid 34755977)
39. Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-215.
40. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359. (Pubitemid 34260428)
41. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790. (Pubitemid 35286287)
42. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444. (Pubitemid 36543357)
43. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. (Pubitemid 41540112)
44. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ 2007; 334: 946-949. (Pubitemid 46808392)
45. Zhang C, Chen H, Xie HH et al. Inflammation is involved in the organ damage induced by sinoaortic denervation in rats. J Hypertens 2003; 21: 2141-2148. (Pubitemid 38296876)
46. Zhang C, Xie HH, Lu ZA et al. Inhibition of inflammation contributes to organ protection of atenolol in sinoaortic-denervated rats. J Cardiovasc Pharmacol 2004; 43: 663-668. (Pubitemid 38534066)
47. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772. (Pubitemid 43323132)
48. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28: 557-563. (Pubitemid 27118377)
49. Yahalom G, Schwartz R, Schwammenthal Y et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009; 40: 1296-1303.
50. Schmitt KE, Edie CF, Laflam P et al. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 2010; 32: 541-548.
51. Cianciaruso B. Conservative therapy Guidelines for chronic renal failure. G Ital Nefrol 2003; 20(Suppl 24): S48-S60.
52. De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69: 538-545. (Pubitemid 43164447)
53. Mancia G, De BG, Dominiczak A et al. 2007; Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
54. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254. (Pubitemid 46768608)
55. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002; 21: 2959-2970.
56. Tripepi G, Jager KJ, Dekker FW et al. Linear and logistic regression analysis. Kidney Int 2008; 73: 806-810. (Pubitemid 351419050)
57. Therneau TM. Martingale-based residuals for survival models. Biometrika 1990; 77: 147-160.